Entrada Therapeutics, Inc. logo TRDA - Entrada Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 4
HOLD 2
SELL 0
STRONG
SELL 0
| PRICE TARGET: $14.00 DETAILS
HIGH: $17.00
LOW: $11.00
MEDIAN: $14.00
CONSENSUS: $14.00
UPSIDE: 180.56%

Stock News

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-44-201. The DMC recommended initiating Cohort 3 at the top dose of 18 mg/kg, an increase from 12 mg/kg in Cohort 2 and 6 mg/kg in Cohort 1.

Oct 14, 2026 03:00 AM • globenewswire.com
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate exposure data -- -- In line with expectations, the secondary objectives demonstrated a 0.10% mean increase in dystrophin production versus baseline in treated participants at the initial dose of 5 mg/kg -- -- Company expects a significant increase in dystrophin production and functional benefit in future cohorts while maintaining a convenient Q6W dosing schedule -- -- ELEVATE-45-201 Cohort 2 enrollment is complete and the Company is on track to report data at the increased dose of 10 mg/kg in the first half of 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45 in ambulatory participants with a confirmed mutation in the DMD gene amenable to exon 45 skipping. Study participants in Cohort 1 received three doses of 5 mg/kg of ENTR-601-45 or placebo.

Oct 14, 2026 03:00 AM • globenewswire.com
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

Entrada Therapeutics is rated Buy with a $8.50 fair value, offering ~52% upside from $5.61, driven by potential validation of its EEV platform. ENTR-601-44's initial dystrophin increase was disappointing, but lower pediatric drug exposure provides a plausible, testable explanation; higher dosing results are expected in Q1 2027. Valuation is anchored by risk-adjusted pipeline estimates and significant cash reserves, with downside to $4–$4.60 if higher dosing fails to deliver.

Oct 09, 2026 10:47 PM • seekingalpha.com
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its 2026 DREAMS Grant Program: a competitive annual program that awards two $50,000 grants in support of projects working to better identify, understand and reach members of the Duchenne muscular dystrophy community who are currently underrepresented or underserved.

Sep 10, 2026 03:00 AM • globenewswire.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purchase 19,425 shares of the Company's common stock to eight newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of September 1, 2026.

Sep 02, 2026 12:30 PM • globenewswire.com
Entrada Therapeutics Reports Second Quarter 2026 Financial Results

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 --  -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business updates. “With multiple data readouts ahead in 2026, we are well positioned to deliver on important clinical milestones and further demonstrate the potential of our DMD franchise,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.

Aug 05, 2026 03:00 AM • globenewswire.com
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study

-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201  -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-45-201. The DMC recommended initiation of the Cohort 2 dose at 10 mg/kg, a dose escalation from 5 mg/kg in Cohort 1.

Jun 02, 2026 03:00 AM • globenewswire.com
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-45-201.

Jun 02, 2026 03:00 AM • globenewswire.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 18,600 restricted stock units (“RSUs”) to three newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of June 1, 2026. The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Jun 01, 2026 12:30 PM • globenewswire.com
INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC

INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC

ATLANTA, May 18, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Entrada Therapeutics, Inc. (“Entrada” or the “Company”) (NASDAQ: TRDA) complied with federal securities laws. On May 7, 2026, Entrada announced ELEVATE-44-201 cohort 1 topline results in its Duchenne muscular dystrophy study. Cohort 1 of the study demonstrated an increase of 2.36% in dystrophin, which fell below analysts' expectations. The price of the Company's stock dropped following this news.

May 18, 2026 04:00 AM • globenewswire.com (Hide legal announcements)

Price Targets